Susan Sgodda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susan Sgodda has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hans-Georg Dederer
Universität Passau
1 shared publication - Luca Lüneburg
Faculty of Law, University of Passau, Passau, Germany
1 shared publication - Sebastian Schleidgen
FernUniversität in Hagen
1 shared publication - Stefan Cravcisin
Faculty of Law, University of Passau, Passau, Germany
1 shared publication - Thomas Heinemann
Institute for Medical Humanities, Medizinische Fakultät, Universitätsklinikum Bonn Bonn Germany
1 shared publication - Tobias Cantz
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany
1 shared publication
Latest Publications
- Open Access
- 11 September 2020
- Published by Springer Nature in BMC Medical Ethics
- Vol. 21 (1) , 1-12
Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy
Background: Clustered Regularly Interspaced Short Palindromic Repeats-associated (CRISPR-Cas) technology may allow for efficient and highly targeted gene editing in single-cell embryos. This possibility brings human germline editing into the focus of ethical and legal debates again. Main body: Against this background, we explore essential ethical and legal questions of interventions into the human germline by means of CRISPR-Cas: How should issues of risk and uncertainty be handled? What responsibilities arise regarding future generations? Under which conditions can germline editing measures be therapeutically legitimized? For this purpose, we refer to a scenario anticipating potential further development in CRISPR-Cas technology implying improved accuracy and exclusion of germline transmission to future generations. We show that, if certain concepts regarding germline editing are clarified, under such conditions a categorical prohibition of one-generation germline editing of single-cell embryos appears not to be ethically or legally justifiable. Conclusion: These findings are important prerequisites for the international debate on the ethical and legal justification of germline interventions in the human embryo as well as for the harmonization of international legal standards.
- 11 September 2020
- Published by Springer Nature in BMC Medical Ethics
- Vol. 21 (1) , 1-12
Open AccessHuman germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy
Background: Clustered Regularly Interspaced Short Palindromic Repeats-associated (CRISPR-Cas) technology may allow for efficient and highly targeted gene editing in single-cell embryos. This possibility brings human germline editing into the focus of ethical and legal debates again. Main body: Against this background, we explore essential ethical and legal questions of interventions into the human germline by means of CRISPR-Cas: How should issues of risk and uncertainty be handled? What responsibilities arise regarding future generations? Under which conditions can germline editing measures be therapeutically legitimized? For this purpose, we refer to a scenario anticipating potential further development in CRISPR-Cas technology implying improved accuracy and exclusion of germline transmission to future generations. We show that, if certain concepts regarding germline editing are clarified, under such conditions a categorical prohibition of one-generation germline editing of single-cell embryos appears not to be ethically or legally justifiable. Conclusion: These findings are important prerequisites for the international debate on the ethical and legal justification of germline interventions in the human embryo as well as for the harmonization of international legal standards.